284 related articles for article (PubMed ID: 34996497)
1. Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.
Müller MR; Burmeister A; Skowron MA; Stephan A; Bremmer F; Wakileh GA; Petzsch P; Köhrer K; Albers P; Nettersheim D
Clin Epigenetics; 2022 Jan; 14(1):5. PubMed ID: 34996497
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
[TBL] [Abstract][Full Text] [Related]
5. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drugs and their molecular targets in testicular germ cell tumours.
Jostes S; Nettersheim D; Schorle H
Nat Rev Urol; 2019 Apr; 16(4):245-259. PubMed ID: 30765888
[TBL] [Abstract][Full Text] [Related]
7. The component of the m
Miranda-Gonçalves V; Lobo J; Guimarães-Teixeira C; Barros-Silva D; Guimarães R; Cantante M; Braga I; Maurício J; Oing C; Honecker F; Nettersheim D; Looijenga LHJ; Henrique R; Jerónimo C
J Exp Clin Cancer Res; 2021 Aug; 40(1):268. PubMed ID: 34446080
[TBL] [Abstract][Full Text] [Related]
8. The Role of
Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
[TBL] [Abstract][Full Text] [Related]
9. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F
World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
12. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.
Koul S; McKiernan JM; Narayan G; Houldsworth J; Bacik J; Dobrzynski DL; Assaad AM; Mansukhani M; Reuter VE; Bosl GJ; Chaganti RS; Murty VV
Mol Cancer; 2004 May; 3():16. PubMed ID: 15149548
[TBL] [Abstract][Full Text] [Related]
13. Emerging Therapeutic Targets for Male Germ Cell Tumors.
Fankhauser CD; Honecker F; Beyer J; Bode PK
Curr Oncol Rep; 2015 Dec; 17(12):54. PubMed ID: 26449842
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
[TBL] [Abstract][Full Text] [Related]
15. N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Nettersheim D; Berger D; Jostes S; Kristiansen G; Lochnit G; Schorle H
Andrology; 2019 Jul; 7(4):498-506. PubMed ID: 30903744
[TBL] [Abstract][Full Text] [Related]
16. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
18.
Kurz L; Miklyaeva A; Skowron MA; Overbeck N; Poschmann G; Becker T; Eul K; Kurz T; Schönberger S; Calaminus G; Stühler K; Dykhuizen E; Albers P; Nettersheim D
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272809
[TBL] [Abstract][Full Text] [Related]
19. Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.
Kalavska K; Conteduca V; De Giorgi U; Mego M
Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
